Although these cells are predicted to be more resistant to conventional chemotherapeutics used for bladder cancer such as cisplatin, gemcitabine, doxorubicin, vinblastine, and mitomycin C, several United States Food and Drug Administration (FDA)-approved agents including omipalisib (PI3K/mTOR inhibitor) and quizartinib (FLT3 inhibitor) were predicted to be more effective against this group of cells (Cluster 13) compared to other tumor cells (Fig. S7). The gene discussed is MTOR; the disease is urinary bladder carcinoma.